NCT05034484已完成1 期
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Treatment-emergent Adverse Events (TEAE)
研究概览
简要总结
This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able and willing to provide written informed consent
- •Body mass index 18 to 32 kg/m2
- •Agree to avoid strenuous physical activity for 2 days prior to each study visit
- •Agree to use highly effective contraception during the study (all participants) and for 90 days after study drug dosing (males) or for 60 days after study drug dosing (females)
- •Male participants must refrain from donating sperm during the study and for 90 days after study drug dosing
- •Female participants must not be pregnant or breastfeeding and must refrain from donating ova during the study and for 60 days after study drug dosing
- •Must have completed vaccination against SARS-CoV-2 at least 4 weeks prior to study drug dosing
排除标准
- •Any current disease, condition, or treatment that could interfere with the study, interfere with interpretation of the data, or pose an unacceptable risk to the participant
- •History or symptoms of significant psychiatric disease; mild, resolved depression or anxiety is acceptable
- •History of immunological disorders, auto-immune disorders, acquired or congenital immune deficiency; see protocol for clarifications/exceptions
- •History of significant hepatic or renal disease or impairment
- •Evidence of an active or suspected cancer or a history of malignancy within the previous 3 years; see protocol for exceptions
- •History of major organ transplantation with an existing functional graft
- •Use or receipt of prescription medications, over-the-counter medications, herbal remedies, or investigation products (study drugs) within protocol-defined timeframes prior to study entry; hormone replacement therapy initiated at least 2 months prior to Screening is acceptable
- •Significant loss of blood or blood product (including donation) over 500 mL or transfusion of any blood product during Screening or within 3 months of Screening
- •Unwilling to refrain from alcohol use ≥ 48 hours prior to Study Day -
- •Known hypersensitivity, allergy, or intolerance to ALPN-303, Fc-based biologic therapy, or any of the excipients contained in the ALPN-303 formulation
- •Immunization with any live vaccine within 6 weeks prior to study drug administration, or expected to require any live vaccines during the study or within 6 weeks after receiving study drug
- •Acceptable laboratory assessments at Screening and Day -1
- •Positive screen for drugs of abuse or alcohol at Screening or Day -1
- •Positive tests for infectious disease (HIV, hepatitis B, hepatitis C, SARS-CoV-2)
- •Acute infection during or within 4 weeks prior to Screening
- •History of frequent or atypical infections as defined per protocol; signs or symptoms of immunodeficiency
- •History or presence of any chronic infectious condition
- •Cardiac risk factors, as defined per protocol
研究组 & 干预措施
ALPN-303 Regimen A
Experimental
干预措施: ALPN-303 (Drug)
Placebo Regimen A
Placebo Comparator
干预措施: Placebo (Drug)
ALPN-303 Regimen B
Experimental
干预措施: ALPN-303 (Drug)
Placebo Regimen B
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Treatment-emergent Adverse Events (TEAE)
时间窗: Day 1 through Day 30
Type, incidence, and severity of TEAE as assessed by CTCAE
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00963768Johnson & Johnson Pharmaceutical Research & Development, L.L.C.116
已完成
1 期
Adult Healthy Volunteers Study to Evaluate ALPN-101 SafetyHealthy VolunteersNCT03748836Alpine Immune Sciences, Inc.96
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male ParticipantsHealthyNCT01840501Janssen Research & Development, LLC108
已完成
2 期
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFRDiabetic NephropathyNCT01756716Mitsubishi Tanabe Pharma Corporation49
已完成
2 期
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With AlbuminuriaDiabetic NephropathyNCT01756703Mitsubishi Tanabe Pharma Corporation67